Literature DB >> 23652031

Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood.

Joanna Y Du1, Puy Sanchez, Lila Kim, Colleen G Azen, David T Zava, Frank Z Stanczyk.   

Abstract

OBJECTIVE: This study aims to investigate the distribution of progesterone in venous whole blood, venous serum, fingertip capillary blood, and saliva after its topical application in both cream and gel formulations.
METHODS: Ten postmenopausal women were randomized to receive 80 mg of progesterone cream or gel applied daily for 14 days, crossing over after a 14-day washout. On the last day of each treatment period, venous blood, fingertip capillary blood, and saliva were sampled frequently for 24 hours after the final application.
RESULTS: After progesterone cream or gel application, serum progesterone levels rose gradually, reaching a peak at 9 and 8 hours, respectively; AUC(0-24) h was significantly higher with cream (12.39 vs 8.32 ng h mL(-1), P = 0.0391). Whole venous blood levels followed a pattern similar to that of serum but were considerably lower. Saliva progesterone showed a peak at 1 and 6 hours after cream and gel application, respectively, and C(max) was comparable with cream and gel. Saliva AUC(0-24) h was substantially higher than the corresponding area under the curve for serum or whole blood but did not differ significantly by delivery method (39.02 and 58.37 ng h mL(-1), P = 0.69). In capillary blood, C(max) was reached at the same time (8 h) and was similar with both formulations; AUC(0-24) h was also similar with both formulations (1,056 ng h mL(-1) for cream and 999 ng h mL(-1) for gel) but was dramatically higher than the corresponding areas under the curve for venous serum and whole blood.
CONCLUSIONS: After application of topical progesterone, saliva and capillary blood levels are approximately 10-fold and 100-fold greater, respectively, than those seen in serum or whole blood. High capillary blood and saliva levels indicate high absorption and transport of progesterone to tissues. Reliance on serum levels of progesterone for monitoring topical dose could lead to underestimation of tissue levels and consequent overdose.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652031     DOI: 10.1097/GME.0b013e31828d39a2

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  8 in total

1.  Contrasting effects of individual versus combined estrogen and progestogen regimens as working memory load increases in middle-aged ovariectomized rats: one plus one does not equal two.

Authors:  Alesia V Prakapenka; Ryoko Hiroi; Alicia M Quihuis; Catie Carson; Shruti Patel; Claire Berns-Leone; Carly Fox; Rachael W Sirianni; Heather A Bimonte-Nelson
Journal:  Neurobiol Aging       Date:  2017-12-07       Impact factor: 4.673

2.  AMH is Higher Across the Menstrual Cycle in Early Postmenarchal Girls than in Ovulatory Women.

Authors:  Madison T Ortega; Lauren Carlson; John A McGrath; Tairmae Kangarloo; Judith Mary Adams; Patrick M Sluss; Geralyn Lambert-Messerlian; Natalie D Shaw
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

3.  The Relationship Between Progesterone, Sleep, and LH and FSH Secretory Dynamics in Early Postmenarchal Girls.

Authors:  Bob Z Sun; Tairmae Kangarloo; Judith M Adams; Patrick Sluss; Donald W Chandler; David T Zava; John A McGrath; David M Umbach; Natalie D Shaw
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

4.  Healthy Post-Menarchal Adolescent Girls Demonstrate Multi-Level Reproductive Axis Immaturity.

Authors:  Bob Z Sun; Tairmae Kangarloo; Judith M Adams; Patrick M Sluss; Corrine K Welt; Donald W Chandler; David T Zava; John A McGrath; David M Umbach; Janet E Hall; Natalie D Shaw
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

5.  Proinflammatory cytokines and DHEA-S in women with fibromyalgia: impact of psychological distress and menopausal status.

Authors:  John A Sturgeon; Beth D Darnall; Heather L Zwickey; Lisa J Wood; Douglas A Hanes; David T Zava; Sean C Mackey
Journal:  J Pain Res       Date:  2014-12-04       Impact factor: 3.133

6.  Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.

Authors:  James H Pickar; Charles Bon; Julia M Amadio; Sebastian Mirkin; Brian Bernick
Journal:  Menopause       Date:  2015-12       Impact factor: 2.953

7.  Testing the influence of testosterone administration on men's honesty in a large laboratory experiment.

Authors:  Austin Henderson; Garrett Thoelen; Amos Nadler; Jorge Barraza; Gideon Nave
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.379

Review 8.  Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.

Authors:  JoAnn V Pinkerton; James H Pickar
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.